$DDXS bottom Pr $0.43 A 9-bagger corrected Oct
Post# of 63893
Posted On: 12/16/2014 7:49:31 AM
$DDXS bottom Pr $0.43
A 9-bagger corrected Oct '12 to Oct '13
diaDexus, Inc .
Receives FDA Clearance for PLAC Activity Test
to Assess Coronary Heart Disease Risk
Website
Shares Outstanding: 55.32M
Float: 32.64M
% Held by Insiders: 29.39%
% Held by Institutions: 3.50%
Shares Short (as of Aug 10, 2004): 0.00
Short Ratio (as of Aug 10, 2004): 0.00
Short % of Float (as of Aug 10, 2004): N/A
Shares Short (prior month): 2.04M
10-Q 11/5/14
Summary
Recent Trades
Headlines
Monday, December 15, 2014
4:44 pm DIADEXUS confirms FDA clearance for PLAC Activity Test to assess coronary heart disease riskBriefing.com (Mon, Dec 15)
diaDexus, Inc. Receives FDA Clearance for PLAC Activity Test to Assess Coronary Heart Disease RiskBusiness Wire (Mon, Dec 15)
Wednesday, December 10, 2014
diaDexus, Inc. Appoints Pat Arensdorf to Lead Heart Failure BusinessBusiness Wire (Wed, Dec 10)
Wednesday, November 19, 2014
DIADEXUS, INC. FinancialsEDGAR Online Financials (Wed, Nov 19)
Friday, November 7, 2014
10-Q for diaDexus, Inc.Company Spotlight (Fri, Nov 7)
Wednesday, November 5, 2014
DIADEXUS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online (Wed, Nov 5)
diaDexus, Inc. Reports Third Quarter 2014 Financial ResultsBusiness Wire (Wed, Nov 5)
Wednesday, October 29, 2014
diaDexus, Inc. to Report Third Quarter 2014 Financial Results on November 5, 2014Business Wire (Wed, Oct 29)
Monday, September 22, 2014
DIADEXUS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online (Mon, Sep 22)
diaDexus, Inc. Announces Appointment of Kenneth Fang, M.D., as Chief Medical OfficerBusiness Wire (Mon, Sep 22)
Thursday, September 11, 2014
DIADEXUS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online (Thu, Sep 11)
Tuesday, September 9, 2014
diaDexus, Inc. Announces Resignation of Chief Financial OfficerBusiness Wire (Tue, Sep 9)
Thursday, August 21, 2014
DIADEXUS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive AEDGAR Online (Thu, Aug 21)
Monday, August 18, 2014
diaDexus, Inc. Secures $15 Million Debt FinancingBusiness Wire (Mon, Aug 18)
Tuesday, August 5, 2014
DIADEXUS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online (Tue, Aug 5)
Monday, July 28, 2014
DIADEXUS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online (Mon, Jul 28)
diaDexus, Inc. Reports Second Quarter 2014 Financial ResultsBusiness Wire (Mon, Jul 28)
Monday, July 21, 2014
diaDexus, Inc. to Host Conference Call and Webcast July 28, 2014 to Discuss Second Quarter 2014 Financial ResultsBusiness Wire (Mon, Jul 21)
Friday, July 18, 2014
DIADEXUS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Fri, Jul 18)
Thursday, July 17, 2014
diaDexus Announces FDA Acceptance for Review of 510(k) Submission for PLAC Test for Lp-PLA2 ActivityBusiness Wire (Thu, Jul 17)
A 9-bagger corrected Oct '12 to Oct '13
diaDexus, Inc .
Receives FDA Clearance for PLAC Activity Test
to Assess Coronary Heart Disease Risk
Website
Shares Outstanding: 55.32M
Float: 32.64M
% Held by Insiders: 29.39%
% Held by Institutions: 3.50%
Shares Short (as of Aug 10, 2004): 0.00
Short Ratio (as of Aug 10, 2004): 0.00
Short % of Float (as of Aug 10, 2004): N/A
Shares Short (prior month): 2.04M
10-Q 11/5/14
Summary
Recent Trades
Headlines
Monday, December 15, 2014
4:44 pm DIADEXUS confirms FDA clearance for PLAC Activity Test to assess coronary heart disease riskBriefing.com (Mon, Dec 15)
diaDexus, Inc. Receives FDA Clearance for PLAC Activity Test to Assess Coronary Heart Disease RiskBusiness Wire (Mon, Dec 15)
Wednesday, December 10, 2014
diaDexus, Inc. Appoints Pat Arensdorf to Lead Heart Failure BusinessBusiness Wire (Wed, Dec 10)
Wednesday, November 19, 2014
DIADEXUS, INC. FinancialsEDGAR Online Financials (Wed, Nov 19)
Friday, November 7, 2014
10-Q for diaDexus, Inc.Company Spotlight (Fri, Nov 7)
Wednesday, November 5, 2014
DIADEXUS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online (Wed, Nov 5)
diaDexus, Inc. Reports Third Quarter 2014 Financial ResultsBusiness Wire (Wed, Nov 5)
Wednesday, October 29, 2014
diaDexus, Inc. to Report Third Quarter 2014 Financial Results on November 5, 2014Business Wire (Wed, Oct 29)
Monday, September 22, 2014
DIADEXUS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online (Mon, Sep 22)
diaDexus, Inc. Announces Appointment of Kenneth Fang, M.D., as Chief Medical OfficerBusiness Wire (Mon, Sep 22)
Thursday, September 11, 2014
DIADEXUS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online (Thu, Sep 11)
Tuesday, September 9, 2014
diaDexus, Inc. Announces Resignation of Chief Financial OfficerBusiness Wire (Tue, Sep 9)
Thursday, August 21, 2014
DIADEXUS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive AEDGAR Online (Thu, Aug 21)
Monday, August 18, 2014
diaDexus, Inc. Secures $15 Million Debt FinancingBusiness Wire (Mon, Aug 18)
Tuesday, August 5, 2014
DIADEXUS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online (Tue, Aug 5)
Monday, July 28, 2014
DIADEXUS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online (Mon, Jul 28)
diaDexus, Inc. Reports Second Quarter 2014 Financial ResultsBusiness Wire (Mon, Jul 28)
Monday, July 21, 2014
diaDexus, Inc. to Host Conference Call and Webcast July 28, 2014 to Discuss Second Quarter 2014 Financial ResultsBusiness Wire (Mon, Jul 21)
Friday, July 18, 2014
DIADEXUS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online (Fri, Jul 18)
Thursday, July 17, 2014
diaDexus Announces FDA Acceptance for Review of 510(k) Submission for PLAC Test for Lp-PLA2 ActivityBusiness Wire (Thu, Jul 17)
(0)
(0)